Drug prescriptions and dementia incidence: a medication-wide association study of 17000 dementia cases among half a million participants

Background Previous studies have suggested that some medications may influence dementia risk. We conducted a hypothesis-generating medication-wide association study to investigate systematically the association between all prescription medications and incident dementia. Methods We used a population-based cohort within the Secure Anonymised Information Linkage (SAIL) databank, comprising routinely-collected primary care, hospital admissions and mortality data from Wales, UK. We included all participants born after 1910 and registered with a SAIL general practice at ≤60 years old. Follow-up was from each participant’s 60th birthday to the earliest of dementia diagnosis, deregistration from a SAIL general practice, death or the end of 2018. We considered participants exposed to a medication if they received ≥1 prescription for any of 744 medications before or during follow-up. We adjusted for sex, smoking and socioeconomic status. The outcome was any all-cause dementia code in primary care, hospital or mortality data during follow-up. We used Cox regression to calculate hazard ratios and Bonferroni-corrected p values. Results Of 551 344 participants, 16 998 (3%) developed dementia (median follow-up was 17 years for people who developed dementia, 10 years for those without dementia). Of 744 medications, 221 (30%) were associated with dementia. Of these, 217 (98%) were associated with increased dementia incidence, many clustering around certain indications. Four medications (all vaccines) were associated with a lower dementia incidence. Conclusions Almost a third of medications were associated with dementia. The clustering of many drugs around certain indications may provide insights into early manifestations of dementia. We encourage further investigation of hypotheses generated by these results.

[1]  Naaheed Mukadam,et al.  Dementia prevention, intervention, and care: 2020 report of the Lancet Commission , 2020, The Lancet.

[2]  C. Sudlow,et al.  Body mass index, diet, physical inactivity, and the incidence of dementia in 1 million UK women , 2019, Neurology.

[3]  C. Sudlow,et al.  The Secure Anonymised Information Linkage databank Dementia e-cohort (SAIL-DeC) , 2019, International journal of population data science.

[4]  J. Hippisley-Cox,et al.  Anticholinergic Drug Exposure and the Risk of Dementia , 2019, JAMA internal medicine.

[5]  C. Sudlow,et al.  Identifying dementia outcomes in UK Biobank: a validation study of primary care, hospital admissions and mortality data , 2019, European Journal of Epidemiology.

[6]  I. Cohen,et al.  Can immunization with Bacillus Calmette-Guérin (BCG) protect against Alzheimer's disease? , 2019, Medical hypotheses.

[7]  C. Sudlow,et al.  Identifying dementia cases with routinely collected health data: A systematic review , 2018, Alzheimer's & Dementia.

[8]  R. Stewart,et al.  Accuracy of general hospital dementia diagnoses in England: Sensitivity, specificity, and predictors of diagnostic accuracy 2008–2016 , 2018, Alzheimer's & Dementia.

[9]  M. Jokela,et al.  Body mass index and risk of dementia: Analysis of individual-level data from 1.3 million individuals , 2018, Alzheimer's & Dementia.

[10]  Carol Brayne,et al.  Anticholinergic drugs and risk of dementia: case-control study , 2018, BMJ.

[11]  A. Tanskanen,et al.  Use of Antiepileptic Drugs and Dementia Risk—an Analysis of Finnish Health Register and German Health Insurance Data , 2018, Journal of the American Geriatrics Society.

[12]  G. Livingston,et al.  A roadmap to advance dementia research in prevention, diagnosis, intervention, and care by 2025 , 2018, International journal of geriatric psychiatry.

[13]  Jean-François Dartigues,et al.  Physical activity, cognitive decline, and risk of dementia: 28 year follow-up of Whitehall II cohort study , 2017, British Medical Journal.

[14]  C. Reynolds,et al.  History of Bipolar Disorder and the Risk of Dementia: A Systematic Review and Meta-Analysis. , 2017, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.

[15]  John P. A. Ioannidis,et al.  Systematic assessment of pharmaceutical prescriptions in association with cancer risk: a method to conduct a population-wide medication-wide longitudinal study , 2016, Scientific Reports.

[16]  John S. Brownstein,et al.  Environment-Wide Association Study of Blood Pressure in the National Health and Nutrition Examination Survey (1999–2012) , 2016, Scientific Reports.

[17]  Shing-Hwa Liu,et al.  Influenza Vaccination Reduces Dementia Risk in Chronic Kidney Disease Patients , 2016, Medicine.

[18]  M. Prince,et al.  World Alzheimer Report 2015 - The Global Impact of Dementia: An analysis of prevalence, incidence, cost and trends , 2015 .

[19]  D. Madigan,et al.  Medication-Wide Association Studies , 2013, CPT: pharmacometrics & systems pharmacology.

[20]  C. Rowe,et al.  Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study , 2013, The Lancet Neurology.

[21]  Nick C Fox,et al.  Clinical and biomarker changes in dominantly inherited Alzheimer's disease. , 2012, The New England journal of medicine.

[22]  Atul J. Butte,et al.  An Environment-Wide Association Study (EWAS) on Type 2 Diabetes Mellitus , 2010, PloS one.

[23]  J. Lindsay,et al.  Past exposure to vaccines and subsequent risk of Alzheimer's disease. , 2001, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[24]  W. Weiner,et al.  Comorbidity of the nonmotor symptoms of Parkinson's disease , 2001, Movement disorders : official journal of the Movement Disorder Society.

[25]  Nick Booth Nhs What are the Read Codes , 1994 .

[26]  N. Booth What are the Read Codes? , 1994, Health libraries review.